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Abstract
Background: Chronic mesenteric ischemia (CMI) is the result of insufficient blood supply to the gastrointestinal tract
and is caused by atherosclerotic stenosis of one or more mesenteric arteries in > 90% of cases. Revascularization
therapy is indicated in patients with a diagnosis of atherosclerotic CMI to relieve symptoms and to prevent acute-on-
chronic mesenteric ischemia, which is associated with high morbidity and mortality. Endovascular therapy has rapidly
evolved and has replaced surgery as the first choice of treatment in CMI. Bare-metal stents (BMS) are standard care
currently, although retrospective studies suggested significantly higher patency rates for covered stents (CS). The
Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI) trial is designed to
prospectively assess the patency of CS versus BMS in patients with atherosclerotic CMI.
Methods/design: The CoBaGI trial is a randomized controlled, parallel-group, patient- and investigator-blinded,
superiority, multicenter trial conducted in six centers of the Dutch Mesenteric Ischemia Study group (DMIS). Eighty-four
patients with a consensus diagnosis of atherosclerotic CMI are 1:1 randomized to either a balloon-expandable BMS
(Palmaz Blue with rapid-exchange delivery system, Cordis Corporation, Bridgewater, NJ, USA) or a balloon-expandable
CS (Advanta V12 over-the-wire, Atrium Maquet Getinge Group, Hudson, NH, USA). The primary endpoint is the primary
stent-patency rate at 24months assessed with CT angiography. Secondary endpoints are primary stent patency at 6
and 12months and secondary patency rates, freedom from restenosis, freedom from symptom recurrence, freedom
from re-intervention, quality of life according the EQ-5D-5 L and SF-36 and cost-effectiveness at 6, 12 and 24months.
Discussion: The CoBaGI trial is designed to assess the patency rates of CS versus BMS in patients treated for CMI
caused by atherosclerotic mesenteric stenosis. Furthermore, the CoBaGI trial should provide insights in the quality of
life of these patients before and after stenting and its cost-effectiveness. The CoBaGI trial is the first randomized
controlled trial performed in CMI caused by atherosclerotic mesenteric artery stenosis.
Trial registration: ClinicalTrials.gov, ID: NCT02428582. Registered on 29 April 2015.
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Background
Chronic mesenteric ischemia (CMI) is the result of insuffi-
cient blood supply to the gastrointestinal (GI) tract and is
caused by atherosclerotic stenosis of one or more
mesenteric arteries in > 90% of cases [1, 2]. The
mesenteric arteries are the celiac artery (CA), superior
mesenteric artery (SMA) and inferior mesenteric artery
(IMA). Classic symptoms of CMI are postprandial
abdominal pain and weight loss due to fear of eating.
However, CMI may present atypically with constant
abdominal discomfort, nausea, vomiting, diarrhea or even
constipation [1]. The “classic triad” of CMI consisting of
postprandial abdominal pain, weight loss and abdominal
bruit is present in only 16–22% of patients [3, 4].
The diagnosis of CMI is established by consensus in a
multidisciplinary meeting joined by vascular surgeons,
gastroenterologists and interventional radiologists [1].
Consensus is an accepted method of diagnosing if a gold
standard test is absent [5]. Symptoms alone do not predict
the diagnosis of CMI accurately [4, 6, 7]. Therefore,
consensus diagnosis is based on the combination of
clinical symptoms, radiological evaluation of the
mesenteric vasculature and, if available, assessment of
mucosal ischemia with a functional test such as gastric-
jejunal tonometry [3, 8, 9] or visible light spectroscopy
(VLS) [10, 11]. A definitive diagnosis of CMI is
established if successful therapy of patients with CMI
consensus diagnosis results in a durable relief of
presenting symptoms.
Revascularization therapy is indicated in patients with
a diagnosis of atherosclerotic CMI to relieve symptoms
and to prevent acute-on-chronic mesenteric ischemia,
which is associated with high morbidity and mortality.
Endovascular revascularization has largely replaced open
surgical revascularization [1, 12, 13]. Endovascular revas-
cularization of the mesenteric arteries is achieved by
means of stent placement. The SMA and CA are target
vessels for therapy because of their larger diameter com-
pared to the IMA. Furthermore, a protective collateral
network ensures blood supply when the IMA is
occluded as shown in patients with an aortic stent
occluding the IMA. Literature on revascularization of
the IMA is scarce. A study reported successful stenting
of the IMA in four patients who were not candidates for
CA or SMA revascularization [14]. The classic percutan-
eous approach for mesenteric endovascular procedure is
trans-brachial and trans-femoral, but a trans-radial
approach is currently gaining popularity [15].
Endovascular revascularization is associated with a
significant decreased risk of in-hospital complications
compared to open mesenteric surgical revasculariza-
tion [16]. Despite the advantages of endovascular
revascularization short term, restenosis is a common
event occurring in 28–55% of patients within 2 years after
endovascular mesenteric stenting [13, 17] whereas 0–25%
of surgically treated patients develop restenosis [2, 18].
The primary patency rate of open surgical revasculariza-
tion is significantly higher than that of endovascular
revascularization (cumulative odds ratio (OR) 3.57, 95%
confidence interval (CI) 1.82–6.87, p = 0.0002, [19].
Currently, balloon-expendable bare-metal stents
(BMS) are standard care for mesenteric endovascular
revascularization [1, 20]. Retrospective data, however,
showed significantly higher primary patency rates of bal-
loon-expendable covered stents (CS) at 3 years for mes-
enteric artery stenosis [21]. Furthermore, patients
treated with CS had less restenosis, symptom recurrence
and re-intervention than patients treated with BMS [21].
The Covered versus Balloon Expandable Stent Trial
(COBEST) showed significantly higher patency rates of
CS than BMS for aortoiliac arterial disease 18, 24, 48
and 60 months after stent placement [22, 23]. Possibly,
the membrane that covers the vascular atherosclerotic
lesion functions as a physical barrier for intimal hyper-
plasia and is, therefore, associated with less restenosis in
contrast with BMS. The performance of CS for mesen-
teric artery stenosis is promising, but prospective con-
firmation is lacking. The CoBaGI trial is a multicenter,
randomized controlled, patient- and investigator-blinded
clinical trial designed to compare patency rates of the
CS versus standard care therapy with BMS in patients
with CMI based on atherosclerosis.
Study hypothesis
CS have a significantly higher patency rate than BMS in
patients with CMI due to stenosis of the CA and/or
SMA of atherosclerotic origin.
Methods/design
This study protocol is written according to the Standard
Protocol Items: Recommendations for Interventional Tri-
als (SPIRIT) 2013 Statement for study protocols of clinical
trials [24]. The SPIRIT Diagram is shown as Table 1 and
the SPIRIT Checklist is added in Additional file 1.
Study design
The CoBaGI trial is a randomized controlled, parallel-
group, patient- and investigator-blinded, superiority,
multicenter trial conducted in six centers of the Dutch
Mesenteric Ischemia Study group (DMIS). Patients
with atherosclerotic CMI will be randomly allocated
to standard care therapy using a BMS (Palmaz Blue
with rapid-exchange delivery system, Cordis Corporation,
Bridgewater, NJ, USA) or a CS (Advanta V12 over-
the-wire, Atrium Maquet Getinge Group, Hudson,
NH, USA).
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Study setting
The CoBaGI trial is conducted within the framework of
the DMIS. Six Dutch centers participate in the CoBaGI
trial. The initiating center is Erasmus MC University
Medical Center, an academic hospital in Rotterdam
together with Medisch Spectrum Twente in Enschede
which serves as a CMI-specialized referral center. Fur-
thermore, four other Dutch tertiary referral centers par-
ticipate in the study: Maasstad Hospital in Rotterdam;
St. Antonius Hospital in Nieuwegein; Bernhoven
Hospital in Uden, and Jeroen Bosch Hospital in ‘s-
Hertogenbosch.
Eligibility criteria
Patients with a consensus diagnosis of atherosclerotic
CMI eligible for endovascular-stent placement will be
included in this trial.
Inclusion criteria are:
 A consensus diagnosis of CMI based on
atherosclerotic mesenteric artery stenosis at the
origin of the CA and/or SMA, established in a
multidisciplinary meeting attended by a
gastroenterologist, interventional radiologist and
vascular surgeon. This consensus diagnosis is
based on:
 Typical symptoms (presence of postprandial pain,
unexplained weight loss)
 Significant stenosis of > 50% of at least one of the
mesenteric arteries on previous computed
tomography angiography (CTA)*
 Functional assessment of mucosal ischemia with
VLS or tonometry
 Aged ≥18 years old
 Signed informed consent
 Total length of mesenteric stenosis < 25 mm
*Requirements for CTA are: CTA performed within
the year before consensus diagnosis maximum slice
thickness 1 mm, enhancement in aorta 300HU.
Exclusion criteria are:
 Absence of informed consent
 Aged < 18 years old
 No stenosis detected during angiography
 Renal insufficiency (glomerular filtration rate (GFR)
below 30 ml/min or GFR below 60 ml/min in the
presence of comorbidities relevant to renal function)
 Previous stent placement in the target vessel
 Pregnancy
 Stenosis based on median arcuate ligament
syndrome (MALS)
 Stenosis based on vasculitis
 Other criteria which the physician considers
incompatible with inclusion in this trial
Recruitment and consent
Patients with CMI based on atherosclerotic mesenteric
artery stenosis are eligible for the CoBaGI trial. A gastro-
enterologist, surgeon or research physician will screen
the patient according to the inclusion and exclusion
criteria. When the patient is eligible for study inclusion,
the treating physician will inform the patient about the
possibility of participating in the CoBaGI trial and will
hand out the patient information form (Additional file
2). Furthermore, the treating physician will inform the
patient that study participation is voluntary and that par-
ticipation may be withdrawn at any time without the
need of having to provide a reason. At the return visit,
the patient is given the opportunity to ask questions. If
the patient consents to participate in the CoBaGI trial,
written informed consent is obtained.
Randomization
Patients are 1:1 randomized for a BMS or CS with a
web-based randomization module (9 Knots Business
Solutions Ltd., Mansfield, UK) in random blocks of
four or six stratified by center.
Table 1 Schedule of enrollment, interventions and assessments
for the CoBaGI trial according to Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) [24]
Study period
Enrollment Allocation Post allocation Close-out
Time point −t1 0 t1 t2 t3 t4 tx
Enrollment:
Eligibility screen X
Informed consent X
Allocation X
Interventions:
Intervention CS X
Intervention BMS X
Assessments:
CTA X X X X
EQ-5D-5 L X X X X
SF-36 X X X X
Cost-effectiveness X X X X
SAE X X X X
Mortality X X X X
−t1 = screening and enrollment, t1 = endovascular-stent placement, t2 = 6
months, t3 = 12 months, t4 = 24months after intervention, tx = end of follow-up
at 24 months
BMS bare-metal stent, CS covered stent, CTA computed tomography
angiography, SAE serious adverse event, SF-36 36-item Short Form
Health Survey
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Interventions
At the start of the endovascular procedure patients are
randomized for either a BMS or CS. The approach of
the intervention is at the discretion of the attending
interventionalist (femoral, brachial, radial or retrograde).
During the angiography the stenoses are assessed and if
a suspected stenosis is not significant, this vessel will not
be treated. If the stenosis is detected to be significant
during angiography and the stenosis length is < 25mm
the stenosis will be treated with the allocated stent. In
case multiple stenosis are present and eligible for inclu-
sion (i.e., CA and SMA), the same allocated stent type is
used. After completion of the intervention various pro-
cedural details, such as duration, approach, stent length,
treated vessels and complications, are entered in web-
based case record forms by the interventionalist. The
antiplatelet regimen in the CoBaGI trial consists of as-
pirin and clopidogrel combined for 12 months followed
by aspirin lifelong and applies for both treatment arms.
Table 1 presents the schedule of enrollment, interven-
tions and assessments for the CoBaGI trial and Fig. 1
presents the Consolidated Standards of Reporting Trials
(CONSORT) study flowchart [25].
Follow-up
After the endovascular procedure, the patients are
followed up at 6, 12 and 24 months with CTA to assess
stent patency and with a visit to the outpatient clinic to
assess symptoms and bodyweight. The patients also
receive questionnaires to assess quality of life and cost-
effectiveness before stent placement and 6, 12 and 24
months after stent placement.
Outcome
The primary endpoint is the primary patency rate 24
months after stent placement based on intention-to-treat
analyses.
The secondary endpoints are (definitions are shown in
Table 2):
 Primary patency rates at 6 and 12months
 Secondary patency rates at 6, 12 and 24 months
 Freedom from restenosis at 6, 12 and 24 months
 Freedom from symptom recurrence at 6, 12 and 24
months
 Freedom from re-intervention at 6, 12 and 24
months
Fig. 1 Flowchart of participants in the Covered stents versus Bare-metal stents in chronic atherosclerotic Gastrointestinal Ischemia (CoBaGI) trial
according to Consolidated Standards of Reporting Trials (CONSORT) [25]
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 Quality of life at 6, 12 and 24 months
 Cost-effectiveness at 6, 12 and 24 months
Blinding
The patient, investigator and the treating physician at
the outpatient clinic are blinded for the treatment allo-
cation (BMS or CS). For the duration of the trial the
allocated stent will not be disclosed unless there is a
medical need (i.e., restenosis, stent fracture).
Sample size
The sample size calculation for this randomized con-
trolled, superiority trial is based on the retrospective
data of Oderich et al. [21]. Assuming that CS improves
the patency rate of BMS after 24 months from 63% to
95%, and accounting for a 20% dropout rate, 42 partici-
pants are required per arm to achieve 80% power with a
two-sided alpha of 0.05. The sample size calculation is
performed using the Comparison of Independent
Proportions Test (SAS Power and Sample size, SAS
Institute Inc., Cary, NC, USA).
Data collection methods
Clinical data are collected using web-based case record
forms (9 Knots Business Solutions Ltd., Mansfield, UK).
Quality of life is assessed by the validated EuroQol five-
dimension, five-level questionnaire (EQ-5D-5 L) [26, 27]
and 36-item Short-Form Health Survey (SF-36) [28, 29]
questionnaires. The cost-effectiveness questionnaire deals
with work omission, hospital visits and use of healthcare.
All trial documents are kept for 15 years after study
completion.
Data management
Data entry is performed by local study personnel or
personnel of the initiating study center. Data entry is
anonymized replacing all patient names with a code.
Only these codes are used as reference in reports and
publications about this investigation. The web-based
case record forms contain range checks for data values.
The handling of personal data is compliant with the
Dutch Personal Data Protection Act, the Code of Good
Behavior and the General Data Protection Regulation ef-
fective since May 2018.
Data monitoring
Institution of a data monitoring committee (DMC) was
waived by the Ethical Committee because the added risk
of the interventional study arm is considered to be negli-
gible. An interim analysis will not be performed. The ini-
tiating center, Erasmus MC University Medical Center,
is responsible for the data monitoring activities to ensure
data quality.
Statistical methods
Descriptive analyses will be provided regarding patient
characteristics before randomization. Because this is a
randomized controlled trial, statistical tests to detect
differences in these baseline characteristics between both
intervention arms will not be performed. The following
patient characteristics before randomization will be
provided: age, gender, Body Mass Index (BMI), smoking
status, comorbidity with hypertension, dyslipidemia, dia-
betes and cardiovascular disease. Furthermore presenting
symptoms will be described as abdominal pain, postpran-
dial pain, exercise-related pain, nausea, diarrhea, weight
loss and symptom duration. Patient characteristics will be
described as numbers and percentages for dichotomous
variables, or as means and standard deviations for con-
tinuous variables with normal distribution or medians and
interquartile ranges (IQRs) for continuous variables if not
normally distributed.
The primary analysis will be performed according the
intention-to-treat principle. A per-protocol analysis will
also be performed for the primary outcome of stent
patency for those patients who were treated according to
the treatment protocol.
The primary endpoint of stent patency will be ana-
lyzed with a “two-sample z-test” for comparison of
two proportions. Furthermore, a predictive model for
time-to-event will be obtained by proportional haz-
ards regression and Kaplan-Meier analysis to compare
patency rates of CS versus BMS. All other continuous
outcome measures will be reported as difference in
mean improvement between the CS versus the BMS
group. Change in quality of life assessed by the vali-
dated questionnaires EQ-5D-5 L [26, 27] and SF-36
[28, 29] will be compared between the CS and BMS
groups. Furthermore, the costs of both groups will be
compared. All costs will be estimated based on actual
input in terms of resource use, personnel and indirect
Table 2 Definitions
Definition
Restenosis > 50% intra-stent stenosis regardless whether the patient had clinical symptoms
Symptom recurrence Occurrence of presenting symptoms regardless of stent patency
Re-intervention Intervention due to symptom occurrence in the presence of > 50% intra-stent
stenosis, either a reimplantation of stent, or a surgical procedure
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costs from loss of productivity assessed by the cost-
effectiveness questionnaire.
Harms
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the study, whether or
not considered related to the implantation of a BMS or
CS. A serious adverse event (SAE) is any untoward
medical occurrence or effect that at any dose:
 Results in death
 Is life threatening (at the time of the event)
 Requires hospitalization or prolongation of existing
inpatients’ hospitalization
 Results in persistent or significant disability or
incapacity
 Is a congenital anomaly or birth defect
 Any other important medical event that may not
result in death, be life threatening or require
hospitalization, may be considered a serious adverse
experience when, based upon appropriate medical
judgment, the event may jeopardize the subject and
may require an intervention to prevent one of the
outcomes listed above
All physicians who are involved in the trial are asked
to report all adverse events to the coordinating investiga-
tor. The coordinating investigator will report the SAEs
through the web portal ToetsingOnline (https://www.
toetsingonline.nl) of the Dutch Central Committee on
Research involving human subjects to the accredited
Institutional Review Board that approved the protocol,
within 15 days after the coordinating investigator has
first knowledge of the serious adverse reactions. Serious
adverse events that result in death or are life threatening
should be reported expedited. The expedited reporting
will occur not later than 7 days after the responsible
investigator has first knowledge of the adverse reaction.
This is for a preliminary report with another 8 days for
completion of the report.
Auditing
Representatives of the initiating center, Erasmus MC
University Medical Center, audit the participating cen-
ters during the course of the study. All protocol modifi-
cations are communicated to the relevant parties.
Research ethics approval
The CoBaGI trial is performed in accordance with
declaration of Helsinki and the Dutch law regarding
research involving human subjects (Wet Medisch
wetenschappelijk Onderzoek met mensen (WMO)). The
Institutional Review Board of Erasmus MC University
Medical Center, Rotterdam, the Netherlands approved
the study protocol on 15 October 2013. The boards of
the other five Dutch participating centers gave permis-
sion for conducting the trial in their center. The CoBaGI
trial was registered on 29 April, 2015 at ClinicalTrials.-
gov with identification number NCT02428582.
Protocol amendments
Five protocol amendments were approved after initial
approval of the CoBaGI protocol by the Institutional
Review Board. The subjects of these amendments were
the addition of new inclusion centers, the addition of
one inclusion criterion and adjustment of the patient
information form. The contents of these amendments
have been incorporated into this protocol.
Confidentially
The investigators and the study staff will keep all infor-
mation about the study patients during and after the
trial in strict confidence. All study data are saved in the
web-based case record forms. This study database is
anonymized, the names of the enrolled study patients
are replaced with a patient study number.
Ancillary and post-trial care
Compensation for post-trial care, for those patients who
suffered harm from trial participation, is covered by trial
health insurance.
Dissemination policy
The study protocol and study results will be presented at
scientific conferences and in peer-reviewed publications.
Authorship eligibility follows the common standards of
author responsibility, conflict of interest, transparency and
the recommendations of the International Committee of
Medical Journal Editors (http://www.icmje.org). There are
no limitations or restrictions for publication.
Discussion
The CoBaGI trial is designed to compare the patency
rate of BMS (standard care) with CS in patients with
CMI based on atherosclerotic mesenteric stenosis.
Besides, the study should provide insights into the
change in quality of life of patients induced by both
stents and their cost-effectiveness. The CoBaGI trial is
the first randomized controlled trial to compare BMS
with CS in patients with CMI based on an atheroscler-
otic mesenteric stenosis.
The recently published clinical practice guidelines of
the European Society of Vascular Surgery (ESVS) recom-
mend with a low level of evidence (C: expert opinion
and/or small studies, retrospective studies) to consider
CS over BMS for patients requiring mesenteric artery
stenting based a single retrospective study by Oderich et
al. [21]. A stronger, level-A recommendation can only be
Dijk et al. Trials          (2019) 20:519 Page 6 of 9
issued based on the results of randomized controlled tri-
als. The optimal design would be a double-blinded con-
trolled trial. Since the physician who performs the
endovascular procedure cannot be blinded, the CoBaGI
trial is designed as a patient- and investigator-blinded,
randomized controlled trial.
The primary endpoint of the CoBaGI trial is primary
stent patency assessed with CTA. The primary endpoint
is a hard endpoint which can be assessed objectively.
The secondary endpoint of symptom recurrence is
dependent on reports of patient and investigator. In
order to ensure unbiased collection and an objective
assessment of the endpoints, blinding of the patient and
investigator is important.
To perform a fair comparison between the two stent
designs all participating centers will use the same brand/
type of BMS as standard of care in the CoBaGI trial.
The initiating center, Erasmus MC University Medical
Center, had already ample experience with the BMS
Palmaz Blue from Cordis for mesenteric stenting and,
therefore, this stent was chosen to be used in all partici-
pating centers. BMS from different manufacturers are
considered comparable in use and outcome although
studies comparing BMS from different manufacturers
are lacking.
Of note is the inclusion criterion that the length of the
stenosis cannot exceed 24 mm because all stenoses need-
ing stent extension had to be excluded in the CoBaGI
trial since a CS will obstruct blood flow when a side-
branch is over-stented in contrast to a BMS. The longest
available Palmaz Blue BMS during the inclusion of the
CoBaGI trial had a length of 24 mm and the longest CS
had a length of 59 mm.
A pivotal inclusion criterion for the CoBaGI trial is a
consensus diagnosis of CMI based on atherosclerotic
mesenteric artery stenosis which is established in a
multidisciplinary meeting joined by gastroenterologists,
interventional radiologists and vascular surgeons. Medisch
Spectrum Twente and Erasmus MC University Medical
Center are specialized CMI referral centers. All patients
eligible for the CoBaGI trial, therefore, will be discussed
during a CMI multidisciplinary meeting in one of these
two centers. If functional assessment of mucosal ischemia
is required to reach a consensus diagnosis, especially in
case of single-vessel disease, the patient is referred to
Erasmus MC University Medical Center (VLS) [10, 11] or
Medisch Spectrum Twente (24-h tonometry) [3, 8, 9].
After endovascular revascularization for CMI, antiplate-
let therapy is recommended and dual antiplatelet therapy
might be considered for 3–12months [1]. Exact dose and
duration schedules are lacking for mesenteric revasculari-
zation. All stented patients in the CoBaGI trial, regardless
of allocation, will receive aspirin and clopidogrel for 12
months after stenting followed by aspirin lifelong.
The true incidence of atherosclerotic CMI is unknown.
It is expected that in the upcoming years the incidence
of atherosclerotic CMI will increase, mainly because of
the aging population and the increasing prevalence of
cardiovascular disease. The predicted increase in the
prevalence of atherosclerotic CMI, the significant patient
burden in terms of pain and loss of quality of life, and,
in particular, the risk of an acute ischemic event with an
exceedingly high mortality risk, underscore the import-
ance of the CoBaGI trial. The CoBaGI trial aimed to
improve the patient outcome in terms of pain relief,
improvement of quality of life and prevention of acute
ischemic events. The fact that the CoBaGI trial is carried
out within the framework of the DMIS with patients
being recruited from multiple academic and community
hospitals should facilitate the generalizability of the
study outcomes.
In conclusion, the CoBaGI trial is a multicenter,
randomized controlled, patient- and investigator-blinded
superiority trial comparing BMS (standard of care) with
CS in patients with CMI caused by an atherosclerotic
stenosis at the origin of the mesenteric artery.
Trial status
The CoBaGI trial started inclusion in May 2015. In
September 2018, 71 patients of the 84 (85%) patients
had been included. Inclusion is expected to be com-
pleted at the end of 2018. Follow-up duration is 2 years.
Latest protocol version is version 5, date 28 June 2017.
Additional files
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 121 kb)
Additional file 2: Translated patient information form of the CoBaGI
trial. (DOCX 46 kb)
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